TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Growth in Participants Treated With Somatropin (Nutropin) Using NuSpin Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Bone age less than or equal to (\</=) 8 years (females) or \</= 10 years (males) as determined by x-ray of the left hand and wrist obtained within six months before enrollment~* Prepubertal males and females by physical exam~* Naive to rhGH therapy~* Diagnosis of IGHD or ISS by standard pharmacologic testing and no other discernable etiology for short stature~* Height standard deviation score (Ht SDS) \</= -1.5 (\</= 5th percentile) for IGHD participants; Ht SDS \</= -2.25 (\</= 1.2 percentile) for ISS participants~Exclusion Criteria:~* Short stature etiologies other than IGHD or ISS~* Participants receiving chronic corticosteroid therapy (greater than \[\>\] 3 months) for other medical conditions~* Participants with active malignancy or any other condition that the investigator believes would pose a significant hazard to the participant if rhGH were initiated~* Females with turner syndrome~* Any previous rhGH treatment~* Participation in another simultaneous medical investigation or trial~* Pediatric participants with closed epiphyses~* Participants prescribed rhGH doses outside the variance of NCGS control participant dosing

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: IGHD participants (Type: None): Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid \[DNA\] origin) (recombinant human growth hormone \[rhGH\]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
- Cohort 2: ISS participants (Type: None): Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple myeloma.~* Status of refractory to or relapsed from at least one prior bortezomib-containing regimen.~* Progressive disease.~* Age \>= 18 years.~* Karnofsky performance status \>= 60%~* Acceptable liver function:~  * Bilirubin =\< 1.5 x ULN (upper limit of normal)~ * Aspartate transaminase (AST) and alanine transaminase (ALT) =\< 3 x ULN~* Acceptable hematologic status:~  * Absolute Neutrophil Count (ANC) \>= 1.5 x 109/L~ * Platelet count \>= 100 x 109/L~ * Hemoglobin \>= 9 g/dL~ * Coagulation status PT-INR/PTT =\< 1.5 x ULN or in the therapeutic range if on anticoagulation therapy. (PT-INR/PTT= prothrombin - international normalized ratio / prothrombin time)~ * Serum potassium within normal range.~* Estimated life expectancy greater than 3 months.~* Signed, written IRB (institutional Review Board)-approved informed consent.~Exclusion Criteria:~* Non-secretory multiple myeloma or symptomatic amyloidosis.~* Hypersensitivity to bortezomib, boron, or mannitol.~* Less than 4 weeks since prior chemotherapy, radiotherapy, endocrine therapy, or immunotherapy, except if disease is rapidly progressing.~* Less than 4 weeks since prior use of other investigational agents.~* Serious concomitant systemic disorders (e.g. active infection).~* Significant cardiovascular disease.~* Marked baseline prolongation of QT/QTc (corrected QT interval)interval.~* Central nervous system disorders requiring neuroleptics / anti-convulsants.~* Peripheral sensory neuropathy of ≥ Grade 2~* Renal insufficiency defined as a creatinine clearance of \< 30 ml/min.~* Non-willingness to use effective contraceptive methods for patients of child-bearing age / potential.~* Pregnant or breast-feeding women.~* Known HIV positivity.~* Prior treatment with belinostat (PXD101), or any other HDAC (histone deacetylase) inhibitor.~* Altered mental status which precludes an understanding of the Informed Consent Document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Wear Characteristics of Denture Teeth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Being treated at UCLA School of Dentistry clinics with implant-assisted mandibular overdentures and conventional maxillary complete dentures or implant overdentures~* Previously treated at UCLA School of Dentistry clinics with implant-assisted mandibular overdentures and conventional maxillary complete dentures or implant overdentures and desires new dentures~* Have healthy, normal soft and hard oral tissues~Exclusion Criteria:~* Oral and medical conditions which would interfere with follow-up evaluations over a two-year period after denture treatment completion~* Abnormal oral soft or hard tissues that prevents conventional denture fabrication~* Impaired dexterity the prevents proper oral hygiene~* Allergy to denture base materials~* Severe parafunction based on current condition of existing dentures~* Any limitation in mouth opening or closing~* Severe TMD symptoms~* Employees (and their immediate families) of the UCLA School of Dentistry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Nano Hybrid Composite Denture teeth (Type: EXPERIMENTAL): Denture teeth are made of nano hybrid composite material

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Infectious Mononucleosis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* mono diagnosis confirmed by lab test~* 21 days or less between start of symptoms and diagnostic test~* presence of fatigue of at least 4/11 (by Chalder Fatigue Questionnaire)~* no other illnesses present~* meets residency requirement~Exclusion Criteria:~* insufficient communication in English~* unable to begin acupuncture within 21 days of diagnostic test~* acupuncture use currently or in the preceding 3 months~* currently under the care of a TCM practitioner~* unwilling to be randomized

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Acupuncture (Type: EXPERIMENTAL): Traditional Chinese acupuncture in conjunction with standard medical care
- Standard medical care (Type: ACTIVE_COMPARATOR): standard medical care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease~* Measurable disease~* Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry~Exclusion Criteria:~* Prior chemotherapy for metastatic disease~* HER2 positive and/or hormonal receptor positive

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Association bevacizumab paclitaxel capecitabine breast cancer (Type: EXPERIMENTAL): * bevacizumab 10 mg/kg in IV, D1 and D15~* paclitaxel 80mg/m2 in IV, D1 to D8 and D15~* capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of probable Alzheimer´s Disease~* Hachinski Ischaemic score \< 4~* MSE score 18 to 24~Exclusion Criteria:~* History of any clinically significant disease or dementia other than Alzheimer´s Disease~* Current major depressive disorder or other major psychiatric disorders

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2,5 mg once daily
- 2 (Type: ACTIVE_COMPARATOR): single dose of 5 mg
- 3 (Type: PLACEBO_COMPARATOR): None
- 4 (Type: EXPERIMENTAL): 60 mg once daily
- 5 (Type: EXPERIMENTAL): 60 mg three times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre to Postoperative Smoking Cessation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Smoker who has surgery scheduled 5-10 weeks in advance~Exclusion Criteria:~* being contraindicated for varenicline use~* evidence of psychiatric instability~* being unwilling/unable to adhere to the study schedule~* be unwilling to provide study access to medical records~* being otherwise judged by the study team to be inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Open-label trial (Type: OTHER): All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with complete resection who are at TNM (primary tumor, regional nodes, metastasis) stage II-Ⅲa, postoperative pathology confirmed for non-small cell lung cancer;~* Has completed four cycle standard solution of adjuvant chemotherapy, or refused to accept the postoperative adjuvant chemotherapy;~* Patients between 18 and 70 years old, no gender restriction;~* Eastern Cooperative Oncology Group (ECOG) PS of two or less;~* Before the start of the study, patient fully understands the study and is willing to sign the informed consent form;~Exclusion Criteria:~* Receiving adjuvant chemotherapy patients started greater than 24 weeks from surgical resection;~* Refused adjuvant chemotherapy patients started greater than 8 weeks from surgical resection;~* Suspected malignant pleural effusion;~* There is no clear pathological diagnosis;~* Combined with other cancer;~* Patient have a positive surgical margin;~* Accept other treatment for lung cancer of postoperative；~* Combined with severe idiopathic disease of liver, kidney and hematopoietic system;~* Combined psychosis or AIDS;~* Allergy to the test drug;~* Pregnant or lactating women;~* Participation in any other clinical trial within three months;~* Conditions that are considered not suitable for this study investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Huaier Granule (Type: EXPERIMENTAL): Huaier Granule
- placebo (Type: PLACEBO_COMPARATOR): placebo
- No-treatment Control (Type: NO_INTERVENTION): patients refused any treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Ventilation Tubes - The SIUTIT Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Children aged 9-36 months.~* Children with at least one Greenlandic born parent with at least one Greenlandic born parent~* American Society of Anaesthesiologists physical status classification class 1 and 2~* B- or C2 - type curve measured by tympanometry at two visits three-four months apart or three episodes of acute otitis media in six months according to medical records or four episodes of acute otitis media in 12 months according to medical records~* Signed informed consent, signed by the legal guardian Exclusion criteria~* Children with orofacial cleft, Downs syndrome or known generalised immune deficiency~* American Society of Anaesthesiologists physical status classification class \> 2.~* Lack of signed informed consent, signed by the legal guardian.~Description of experimental and control intervention Experimental intervention: The intervention group will be treated with bilateral Donaldson ventilation tubes administered in general anaesthesia Control intervention: The control intervention is based on the current practice in Greenland, which includes systemic antibiotic treatment as well as aural toilette and topical antibiotics. Ventilation tube insertion during the study period is not accepted in the control group.~Children in the intervention group as well as the control group will be seen once a year by the visiting ear-nose-and throat (ENT)-specialist and have a final consultation after at least two years after randomisation.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 36 Months
- Healthy Volunteers: f

Study Arms:
- Ventilation tube treatment (Type: EXPERIMENTAL): Ventilation tube insertion in the tympanic membrane
- Conservative treatment (Type: NO_INTERVENTION): Conventional treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Gralise® for Chronic Pelvic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and older~* English speaking~* able to give consent~* willing to use electronic diary during entire length of the study~* has 'chronic' pelvic pain~* Meets one of the following diagnostic criteria for one of the following: Irritable Bowel Syndrome (IBS) Ulcerative Colitis (UC), Interstitial Cystitis (IC), and Prostatitis~Exclusion Criteria:~* allergic to gabapentin or inactive ingredients~* taking gabapentinoids (i.e. gabapentin or pre-gabalin)~* with severe or unmanaged psychiatric disturbance (at PI discretion)~* with severe ongoing or unaddressed medical conditions (esp. Renal or Hepatic disease, uncontrolled hypertension), rheumatologic disease, narrow angle glaucoma, hyponatremia, clotting disorders, uncontrolled seizure disorder or urinary retention.~* who plan to change their therapeutic regimen during the course of the trial (e.g. start physical therapy, massage, medications, injections, etc.)~* with acute pain~Female subjects:~* pregnant or plan to become pregnant~* gave birth within the last 6 months~* breastfeeding~* episodic visceral pain (e.g. endometriosis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo then Gralise (Type: PLACEBO_COMPARATOR): Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
- Gralise then Placebo (Type: ACTIVE_COMPARATOR): Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2127399 in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of adult onset RA disease according to revised 1987 American Rheumatism Association (ARA) criteria and currently have a documented history of positive for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP Ab) and have moderately to severely active RA despite ongoing methotrexate (MTX) therapy~* Have active RA defined as the presence of at least 8/68 tender and at least 8/66 swollen joints, as determined by the tender joint count and swollen joint count assessment forms~* Have a screening C-reactive protein (CRP) measurement greater than 1.2 times upper limit of normal or erythrocyte sedimentation rate (ESR) greater than 28 millimeters/hour (mm/hr)~* Have a clinically inflamed joint suitable for synovial biopsy procedure~Exclusion Criteria:~* Have used an unstable dose of non-steroidal anti-inflammatory drugs (NSAIDs) within 6 weeks prior to baseline~* Have used oral corticosteroids at average daily doses of \>10 milligrams/day (mg/day) of prednisone or its equivalent within 6 weeks prior to baseline~* Have received any parenteral corticosteroid injection within 6 weeks of baseline~* Have used other disease-modifying anti-rheumatic drugs (DMARDs) other than MTX, hydroxychloroquine, and/or sulfasalazine in the 8 weeks prior to baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2127399 (Type: EXPERIMENTAL): LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed melanoma metastatic to regional lymph nodes with a clinically palpable mass Must have clinical evidence of the following: Metastases in 1 nodal site All other nodes microscopically negative No intransit metastases No extranodal extension OR Metastases in more than 1 nodal site More than 1 positive lymph node in a single site Intransit metastases Extranodal extension Must have undergone complete resection of tumor, measuring at least 2 cm in diameter, within the past 6 weeks No distant metastases~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 80-100% Life expectancy: At least 6 months Hematopoietic: Hematocrit at least 30% WBC at least 3,000/mm3 Hepatic: Hepatitis B and C negative Renal: Not specified Other: Not pregnant or nursing No active serious infection No active autoimmune disease HIV negative No other malignancy within the last 5 years except squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder carcinoma, early stage prostate cancer, or noninvasive melanoma No active severe depression or psychiatric disorder with psychotic symptoms No uncontrolled thyroid abnormalities~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks since prior cytotoxic drugs (except for isolated limb perfusion) Endocrine therapy: No concurrent systemic corticosteroids Radiotherapy: At least 6 months since prior radiotherapy Surgery: See Disease Characteristics Other: At least 30 days since prior investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues